Prostatic urethral lift: A minimally invasive treatment for benign prostatic hyperplasia

Cindy Garcia; Peter Chin; Prem Rashid; Henry H Woo

doi:10.1016/j.prnil.2015.02.002

Prostatic urethral lift: A minimally invasive treatment for benign prostatic hyperplasia

Prostate Int. 2015 Mar;3(1):1-5. doi: 10.1016/j.prnil.2015.02.002. Epub 2015 Feb 13.

Authors

Cindy Garcia¹, Peter Chin², Prem Rashid³, Henry H Woo¹

Affiliations

¹ Sydney Adventist Hospital Clinical School, University of Sydney, NSW, Australia.
² Department of Urology, The Wollongong Hospital, Wollongong, NSW, Australia ; Graduate School of Medicine, University of Wollongong, NSW, Australia ; Figtree Private Hospital, Figtree, NSW, Australia.
³ Department of Urology, Port Macquarie Base Hospital, NSW, Australia ; Rural Clinical School, The University of New South Wales, Port Macquarie, NSW, Australia.

Abstract

Prostatic urethral lift (PUL) is a minimally invasive procedure for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. The procedure may be performed under local, spinal, or general anesthesia. The PUL procedure involves the delivery of implants that retract obstructing prostate lobes. Unlike other benign prostatic hyperplasia treatment options including pharmacological therapy, and the current invasive gold-standard transurethral resection of the prostate, the PUL procedure achieves quantifiable improvements in functional outcomes and quality of life, in the absence of major adverse events. Furthermore, improvement in LUTS may be attained while preserving erectile and ejaculatory function. Adverse effects associated with the PUL procedure are mild to moderate, and are transient in nature. The PUL procedure provides an alternative for men seeking treatment for bothersome LUTS, with fewer side-effects.

Keywords: Benign prostatic hyperplasia; Minimally invasive surgery; Prostatic urethral lift; Urolift.

Publication types

Review